These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


274 related items for PubMed ID: 15780954

  • 1. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 2. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 3. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 17; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 4. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 5. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M, Amano S.
    J Bone Miner Metab; 2004 Aug 25; 22(5):415-29. PubMed ID: 15316862
    [Abstract] [Full Text] [Related]

  • 6. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct 25; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF.
    Biochem Pharmacol; 2005 Jul 15; 70(2):300-7. PubMed ID: 15919055
    [Abstract] [Full Text] [Related]

  • 8. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS.
    J Endocrinol; 2005 Jun 15; 185(3):401-13. PubMed ID: 15930166
    [Abstract] [Full Text] [Related]

  • 9. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan 15; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2005 Oct 15; 37(10):589-92. PubMed ID: 16278780
    [Abstract] [Full Text] [Related]

  • 12. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH.
    Free Radic Biol Med; 2006 May 01; 40(9):1483-93. PubMed ID: 16632109
    [Abstract] [Full Text] [Related]

  • 13. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF, Lie A, Ransjö M.
    J Cell Biochem; 2006 Oct 01; 99(2):528-37. PubMed ID: 16639710
    [Abstract] [Full Text] [Related]

  • 14. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.
    Biochem Biophys Res Commun; 2005 Mar 04; 328(1):91-7. PubMed ID: 15670755
    [Abstract] [Full Text] [Related]

  • 15. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC.
    J Cell Physiol; 2005 Jun 04; 203(3):573-82. PubMed ID: 15573398
    [Abstract] [Full Text] [Related]

  • 16. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
    Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, Brazier M.
    J Cell Biochem; 2004 May 15; 92(2):285-95. PubMed ID: 15108355
    [Abstract] [Full Text] [Related]

  • 17. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H, Murakami A, Aggarwal BB.
    Mol Cancer Res; 2006 Apr 15; 4(4):275-81. PubMed ID: 16603641
    [Abstract] [Full Text] [Related]

  • 18. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.
    Rev Invest Clin; 2001 Apr 15; 53(4):362-9. PubMed ID: 11599485
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.
    J Cell Physiol; 2008 Nov 15; 217(2):409-22. PubMed ID: 18543257
    [Abstract] [Full Text] [Related]

  • 20. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY.
    Biochem Biophys Res Commun; 2004 Dec 24; 325(4):1472-80. PubMed ID: 15555594
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.